Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following drugs is NOT a centrally acting antagonist used in opioid dependency?

naldemedine. ### Explanation The key to answering this question lies in distinguishing between **centrally acting** and **peripherally acting** opioid antagonists. **1. Why Naldemedine is the correct answer:** Naldemedine is a **PAMORA** (Peripherally Acting Mu-Opioid Receptor Antagonist). It is chemically modified (by adding a side chain) to prevent it from crossing the blood-brain barrier (BBB) [4]. Because it acts only on receptors in the gastrointestinal tract without reversing central analgesia or affecting dependency, it is used specifically for **Opioid-Induced Constipation (OIC)**. It has no role in treating opioid dependency or overdose. **2. Analysis of Incorrect Options:** * **Naloxone (A):** A competitive antagonist at all opioid receptors. It crosses the BBB rapidly but has poor oral bioavailability [1]. It is the drug of choice for **acute opioid overdose** [3]. Additionally, in opioid-dependent patients, it precipitates a withdrawal syndrome [2]. * **Naltrexone (D):** A long-acting central antagonist with good oral bioavailability. It is primarily used for **relapse prevention** in opioid and alcohol dependency [4]. * **Nalmefene (B):** Similar to naltrexone but with a longer half-life [1]. It is used for treating alcohol dependence and, in some regions, opioid overdose [4]. **3. NEET-PG High-Yield Pearls:** * **PAMORAs:** Remember the "3 M's and an N" for Opioid-Induced Constipation: **M**ethylnaltrexone, **M**ovantik (Naloxegol), **M**aluby (Naldemedine), and **A**lvimopan. * **Alvimopan** is specifically used to accelerate bowel recovery after major surgery (Post-operative ileus). * **Naltrexone** is also FDA-approved for **Alcohol Use Disorder** as it reduces the "reward" or craving by blocking endogenous opioid release. * **Naloxone** is often combined with Buprenorphine (Suboxone) to prevent intravenous abuse of the oral formulation [5].

Q: Which of the following is NOT used in the acute management of gout?

Allopurinol. The management of gout is divided into two distinct phases: **Acute Attack Management** (to reduce inflammation) and **Chronic Prophylaxis** (to lower serum uric acid). ### 1. Why Allopurinol is the Correct Answer **Allopurinol** is a xanthine oxidase inhibitor used for **hypouricemic therapy**. It is contraindicated during an acute attack because a rapid fluctuation in serum urate levels can cause the mobilization of urate crystals from tissue stores into the joint space, potentially **worsening or prolonging the acute inflammation**. It should only be started 2–4 weeks after the acute episode has completely resolved. ### 2. Analysis of Incorrect Options * **NSAIDs (e.g., Indomethacin, Naproxen):** These are the first-line agents for acute gout. They work by inhibiting prostaglandin synthesis, thereby reducing pain and inflammation. * **Corticosteroids (e.g., Prednisolone):** Used when NSAIDs or Colchicine are contraindicated (e.g., renal failure). They can be administered orally, intravenously, or intra-articularly. * **Colchicine:** A specific anti-gout drug that inhibits microtubule polymerization and leukocyte migration. It is highly effective if started within 24–36 hours of symptom onset. ### 3. NEET-PG High-Yield Pearls * **Drug of Choice (DOC):** NSAIDs are generally the DOC for acute gout; however, if the patient has peptic ulcer disease or renal insufficiency, **Corticosteroids** are preferred. * **The "Allopurinol Paradox":** If a patient is *already* on Allopurinol when an acute attack starts, do **not** stop it. If they are not on it, do **not** start it. * **Febuxostat:** Another xanthine oxidase inhibitor used for chronic management, preferred in patients with mild-to-moderate renal impairment. * **Aspirin:** Avoid in gout as low doses inhibit uric acid excretion in the tubules, worsening hyperuricemia.

Q: Pure opiate antagonists are all of the following except:

Nalorphine. **Explanation:** The classification of opioid ligands is based on their activity at the opioid receptors ($\mu$, $\kappa$, and $\delta$). **1. Why Nalorphine is the correct answer:** Nalorphine is a **mixed agonist-antagonist**, not a pure antagonist. It acts as a competitive antagonist at $\mu$ receptors but exhibits partial agonist activity at $\kappa$ receptors. Because it possesses intrinsic agonistic activity, it can induce side effects like dysphoria and hallucinations, and it may even cause respiratory depression in opioid-naive individuals. Therefore, it is not classified as a "pure" antagonist. **2. Why the other options are incorrect:** * **Naloxone (A):** A pure competitive antagonist at $\mu$, $\kappa$, and $\delta$ receptors with no intrinsic activity. It is the drug of choice for acute opioid poisoning due to its rapid onset (given IV). * **Naltrexone (D):** A pure antagonist similar to naloxone but with higher oral bioavailability and a significantly longer half-life. It is primarily used for maintenance therapy in opioid addicts and for reducing alcohol cravings. * **Nalmefene (C):** A newer pure opioid antagonist. Like naltrexone, it is orally active and has a long half-life, used in managing alcohol dependence. **High-Yield Clinical Pearls for NEET-PG:** * **Pure Antagonists:** Naloxone, Naltrexone, Nalmefene (Mnemonic: The "**Nal-**" drugs without an "**-orph-**" in the middle). * **Mixed Agonist-Antagonists:** Nalorphine, Pentazocine, Butorphanol, Nalbuphine. * **Naloxone Challenge:** Used to diagnose physical dependence before starting naltrexone. * **Methylnaltrexone/Alvimopan:** Peripheral $\mu$-antagonists used to treat opioid-induced constipation without reversing analgesia.

Q: Naloxone for opioid receptor acts as:

Pure antagonist. **Naloxone** is the prototype **pure opioid antagonist** [1, 2]. It has a high affinity for all three opioid receptors (μ, κ, and δ) but lacks intrinsic activity [1]. It works by competitively displacing opioids from their receptors, thereby reversing all opioid effects, including respiratory depression and sedation [1].* **Why Option B is Correct:** Naloxone is a "pure" antagonist because it produces no pharmacological effect of its own when administered alone [1]. It only acts in the presence of an agonist (like Morphine or Heroin) to block or reverse its action.* **Why Option A is Incorrect:** A pure agonist (e.g., Morphine, Fentanyl) binds to the receptor and produces a maximal functional response.* **Why Option C is Incorrect:** A partial agonist (e.g., Buprenorphine) binds to the receptor but produces a sub-maximal response even at high doses [3].* **Why Option D is Incorrect:** Agonist-antagonists (e.g., Pentazocine, Nalbuphine) act as an agonist at one receptor (usually κ) and an antagonist at another (usually μ).**High-Yield Clinical Pearls for NEET-PG:**1. **Drug of Choice:** Naloxone is the DOC for **acute opioid poisoning** [1].2. **Pharmacokinetics:** It has a very short duration of action (30–90 minutes) and poor oral bioavailability due to extensive first-pass metabolism; hence, it is given IV/IM/Intranasal.3. **Naltrexone vs. Naloxone:** Unlike Naloxone, **Naltrexone** is orally active and long-acting, making it the drug of choice for **preventing relapse** in detoxified opioid addicts and for treating alcohol dependence.4. **Methylnaltrexone:** A peripheral μ-antagonist used specifically for opioid-induced constipation without reversing analgesia [1].

Q: Which of the following drugs can cause oligospermia?

Methotrexate. **Explanation:** **Correct Option: A. Methotrexate** Methotrexate (MTX) is a folic acid antagonist that inhibits the enzyme **dihydrofolate reductase (DHFR)**. This inhibition leads to a depletion of tetrahydrofolate, which is essential for DNA synthesis and cell division. Because spermatogenesis is a process involving rapid cellular proliferation, the testes are highly sensitive to the cytotoxic effects of MTX. It can cause **oligospermia** (low sperm count), reversible infertility, and chromosomal damage in sperm. Clinically, male patients are advised to discontinue MTX at least 3 months before attempting conception. **Analysis of Incorrect Options:** * **B. Hydroxychloroquine:** This is an antimalarial and DMARD used in SLE and RA. It is generally considered safe regarding male fertility and is one of the few DMARDs safe during pregnancy. * **C. Leflunomide:** This drug inhibits **dihydroorotate dehydrogenase**, affecting pyrimidine synthesis. While it is highly teratogenic (Category X) and requires a "washout" procedure with cholestyramine, it is not a classic cause of oligospermia compared to MTX. * **D. D-penicillamine:** A chelating agent used in Wilson’s disease and formerly in RA. Its primary side effects include nephrotic syndrome, pemphigus, and myasthenia-like syndrome, but not oligospermia. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing oligospermia:** Sulfasalazine (very common high-yield fact), Cyclophosphamide (can cause permanent azoospermia), Cimetidine, and Anabolic steroids. * **Sulfasalazine vs. Methotrexate:** Sulfasalazine-induced oligospermia is typically reversible within 2–3 months of discontinuation. * **Rescue Therapy:** Leucovorin (folinic acid) is used to "rescue" normal cells from MTX toxicity but does not always prevent gonadal impact.

Q: Which physiological effect is NOT produced by stimulation of the Kappa opioid receptor?

Constipation. **Explanation:** The correct answer is **Constipation**. While constipation is a hallmark side effect of opioid analgesics, it is primarily mediated by **Mu (μ) receptors** located in the gastrointestinal tract, which decrease motility. Stimulation of **Kappa (κ) receptors** has a negligible effect on bowel motility. **Analysis of Options:** * **Sedation (A):** Kappa receptor stimulation produces significant sedation and dysphoria. Unlike Mu-mediated euphoria, Kappa agonists often cause a "flat" or unpleasant sedative effect. * **Diuresis (B):** This is a high-yield distinction. While Mu receptors cause urinary retention (by increasing sphincter tone), Kappa receptors **inhibit the release of ADH (Vasopressin)** at the posterior pituitary, leading to free water clearance and diuresis. * **Miosis (C):** Both Mu and Kappa receptors contribute to pupillary constriction (miosis) via the stimulation of the Edinger-Westphal nucleus. * **Constipation (D):** As noted, this is a Mu-receptor-mediated effect. Kappa agonists do not significantly delay gastric emptying or cause constipation. **Clinical Pearls for NEET-PG:** * **Receptor Triad:** Remember the "Big Three": **Mu** (Analgesia, Euphoria, Respiratory Depression, Constipation), **Kappa** (Analgesia, Dysphoria, Diuresis, Sedation), and **Delta** (Analgesia, Seizures). * **Dysphoria:** A key differentiator; Mu = Euphoria, Kappa = Dysphoria/Hallucinations. * **Respiratory Depression:** Kappa receptors produce much less respiratory depression compared to Mu receptors, providing a "ceiling effect." * **Mixed Agonist-Antagonists:** Drugs like **Pentazocine** and **Butorphanol** act primarily as Kappa agonists and Mu antagonists/partial agonists.

Q: Which opioid has monoamine activity?

Tramadol. **Explanation:** **Tramadol** is a unique, centrally acting analgesic with a **dual mechanism of action** [2]. It acts as a weak agonist at **$\mu$-opioid receptors** and, more significantly, exhibits **monoamine activity** by inhibiting the neuronal reuptake of **Serotonin (5-HT)** and **Norepinephrine (NE)** [2]. This enhances the descending inhibitory pathways in the spinal cord, providing effective pain relief with a lower risk of respiratory depression compared to traditional opioids. **Analysis of Incorrect Options:** * **Pentazocine:** This is an opioid agonist-antagonist ($\kappa$-agonist and $\mu$-antagonist/partial agonist). It does not possess significant monoamine reuptake inhibition properties. * **Pethidine (Meperidine):** These are the same drug (Pethidine is the international non-proprietary name for Meperidine) [1]. While Pethidine can interact with serotonergic drugs to cause **Serotonin Syndrome** (due to its metabolite normeperidine), its primary analgesic action is via $\mu$-opioid receptors and local anesthetic-like effects, not direct monoamine reuptake inhibition [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Tapentadol:** Like Tramadol, it also has dual action (NE reuptake inhibition + $\mu$-agonism) but has negligible effect on Serotonin. * **Seizure Risk:** Tramadol lowers the seizure threshold; avoid in patients with epilepsy. * **Serotonin Syndrome:** Caution must be exercised when prescribing Tramadol with SSRIs or MAO inhibitors due to the risk of Serotonin Syndrome [3]. * **Antidote:** Naloxone only partially reverses the analgesic effects of Tramadol because it only blocks the opioid component, not the monoamine component [2].

Q: Infliximab is directed against which of the following?

Tumor necrosis factor-alpha (TNF-alpha). **Explanation:** **Infliximab** is a chimeric monoclonal antibody (composed of human constant and murine variable regions) that binds with high affinity to both soluble and transmembrane forms of **Tumor Necrosis Factor-alpha (TNF-α)** [2], [3]. By neutralizing TNF-α, it prevents the cytokine from binding to its receptors, thereby inhibiting the downstream inflammatory cascade [3]. This makes it highly effective in treating autoimmune conditions like Rheumatoid Arthritis, Crohn’s disease, and Ankylosing Spondylitis [1], [2]. **Analysis of Incorrect Options:** * **Interleukin-1 (IL-1):** This is the target of **Anakinra** (a recombinant IL-1 receptor antagonist) [2]. * **Interleukin-12 (IL-12):** This, along with IL-23, is targeted by **Ustekinumab**, commonly used in psoriasis and psoriatic arthritis. * **Intercellular Adhesion Molecule (ICAM):** While ICAM-1 is involved in leukocyte trafficking, drugs like **Efalizumab** (now withdrawn) targeted LFA-1 to prevent binding to ICAM, but Infliximab has no direct action here. **High-Yield Clinical Pearls for NEET-PG:** * **TNF-α Inhibitors:** Other examples include **Adalimumab** (fully human mAb) and **Etanercept** (a decoy receptor/fusion protein) [1], [2], [4]. * **Pre-treatment Screening:** Before starting Infliximab, patients **must** be screened for **Latent Tuberculosis** (using TST or IGRA) because TNF-α is essential for granuloma maintenance; inhibiting it can lead to TB reactivation. * **Adverse Effects:** Increased risk of serious infections, infusion reactions, and potential worsening of heart failure [2].

Question 1

Which of the following drugs is NOT a centrally acting antagonist used in opioid dependency?

Accepted Answer

naldemedine

Answer

naloxone

Answer

nalmefene

Answer

naltrexone

Question 2

Which of the following is NOT used in the acute management of gout?

Accepted Answer

Allopurinol

Answer

NSAIDs

Answer

Corticosteroids

Answer

Colchicine

Question 3

Pure opiate antagonists are all of the following except:

Accepted Answer

Nalorphine

Answer

Naloxone

Answer

Nalmefene

Answer

Naltrexone

Question 4

Naloxone for opioid receptor acts as:

Accepted Answer

Pure antagonist

Answer

Pure agonist

Answer

Partial agonist

Answer

Agonist antagonist

Question 5

Which of the following drugs can cause oligospermia?

Accepted Answer

Methotrexate

Answer

Hydroxychloroquine

Answer

Leflunomide

Answer

D-penicillamine

Question 6

Which physiological effect is NOT produced by stimulation of the Kappa opioid receptor?

Accepted Answer

Constipation

Answer

Sedation

Answer

Diuresis

Answer

Miosis

Question 7

True regarding morphine?

Accepted Answer

Tolerance develops for all effects except miosis and constipation.

Answer

Tolerance to all effects develops with chronic usage.

Answer

Tolerance develops for all effects except euphoria and sedation.

Answer

Tolerance can develop to all effects in high doses.

Question 8

Which opioid has monoamine activity?

Accepted Answer

Tramadol

Answer

Pentazocine

Answer

Pethidine

Answer

Meperidine

Question 9

Infliximab is directed against which of the following?

Accepted Answer

Tumor necrosis factor-alpha (TNF-alpha)

Answer

Interleukin-1 (IL-1)

Answer

Interleukin-12 (IL-12)

Answer

Intercellular adhesion molecule (ICAM)

Question 10

Aspirin protects against which of the following conditions?

Accepted Answer

Liver cancer

Answer

Myocardial infarction

Answer

Stroke

Answer

Colorectal cancer

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?